mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma
Opinion statement Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (...
Gespeichert in:
| Veröffentlicht in: | Current treatment options in oncology 2012-03, Vol.13 (1), p.71-81 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81 |
|---|---|
| container_issue | 1 |
| container_start_page | 71 |
| container_title | Current treatment options in oncology |
| container_volume | 13 |
| creator | Nguyen, Shaun A. Walker, David Gillespie, M. Boyd Gutkind, J. Silvio Day, Terry A. |
| description | Opinion statement
Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the three rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive preclinical data suggests that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients. |
| doi_str_mv | 10.1007/s11864-011-0180-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1111872400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788417831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-7cc6cd4cca61567bdce6d73a369e7400be3f940e88bc4402313c6202d4bebc2e3</originalsourceid><addsrcrecordid>eNp1kFFLwzAQx4Mobk4_gC8S8LmaXLKmfZShbjAczOlrSNOr61zbLWkf_PZmVsUXA0cO7nf_gx8hl5zdcMbUrec8iWXEOA-VsAiOyJCPhYxiUOr40IOKQEE6IGfebxiDsWTpKRkAQAIilUPyWq0WSzqr12VWto3z1NQ5LVtPl80WaVnTdo105dC0FdYtbQo6RZN_UU9o3-nzvjNV03k6we2WToyzZd1U5pycFGbr8eL7H5GXh_vVZBrNF4-zyd08slKoNlLWxjaX1pqYj2OV5RbjXAkj4hSVZCxDUaSSYZJkVkoGggsbA4NcZphZQDEi133uzjX7Dn2rN03n6nBS8_ASBSElULynrGu8d1jonSsr4z40Z_pgUvcmdTCpDyY1hJ2r7-QuqzD_3fhRFwDoAR9G9Ru6P6f_Tf0ErMx8uQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1111872400</pqid></control><display><type>article</type><title>mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nguyen, Shaun A. ; Walker, David ; Gillespie, M. Boyd ; Gutkind, J. Silvio ; Day, Terry A.</creator><creatorcontrib>Nguyen, Shaun A. ; Walker, David ; Gillespie, M. Boyd ; Gutkind, J. Silvio ; Day, Terry A.</creatorcontrib><description>Opinion statement
Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the three rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive preclinical data suggests that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-011-0180-2</identifier><identifier>PMID: 22282394</identifier><language>eng</language><publisher>New York: Current Science Inc</publisher><subject>Antineoplastic Agents - pharmacokinetics ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - epidemiology ; Carcinoma, Squamous Cell - genetics ; Clinical Trials as Topic ; Everolimus ; Female ; Head and Neck Cancer (T Day ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - epidemiology ; Head and Neck Neoplasms - genetics ; Humans ; Male ; Medicine ; Medicine & Public Health ; Oncology ; Section Editor ; Signal Transduction ; Sirolimus - analogs & derivatives ; Sirolimus - pharmacokinetics ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; United States - epidemiology</subject><ispartof>Current treatment options in oncology, 2012-03, Vol.13 (1), p.71-81</ispartof><rights>Springer Science+Business Media, LLC 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-7cc6cd4cca61567bdce6d73a369e7400be3f940e88bc4402313c6202d4bebc2e3</citedby><cites>FETCH-LOGICAL-c437t-7cc6cd4cca61567bdce6d73a369e7400be3f940e88bc4402313c6202d4bebc2e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-011-0180-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-011-0180-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22282394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Shaun A.</creatorcontrib><creatorcontrib>Walker, David</creatorcontrib><creatorcontrib>Gillespie, M. Boyd</creatorcontrib><creatorcontrib>Gutkind, J. Silvio</creatorcontrib><creatorcontrib>Day, Terry A.</creatorcontrib><title>mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement
Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the three rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive preclinical data suggests that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients.</description><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - epidemiology</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Clinical Trials as Topic</subject><subject>Everolimus</subject><subject>Female</subject><subject>Head and Neck Cancer (T Day</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - epidemiology</subject><subject>Head and Neck Neoplasms - genetics</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Section Editor</subject><subject>Signal Transduction</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - pharmacokinetics</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>United States - epidemiology</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kFFLwzAQx4Mobk4_gC8S8LmaXLKmfZShbjAczOlrSNOr61zbLWkf_PZmVsUXA0cO7nf_gx8hl5zdcMbUrec8iWXEOA-VsAiOyJCPhYxiUOr40IOKQEE6IGfebxiDsWTpKRkAQAIilUPyWq0WSzqr12VWto3z1NQ5LVtPl80WaVnTdo105dC0FdYtbQo6RZN_UU9o3-nzvjNV03k6we2WToyzZd1U5pycFGbr8eL7H5GXh_vVZBrNF4-zyd08slKoNlLWxjaX1pqYj2OV5RbjXAkj4hSVZCxDUaSSYZJkVkoGggsbA4NcZphZQDEi133uzjX7Dn2rN03n6nBS8_ASBSElULynrGu8d1jonSsr4z40Z_pgUvcmdTCpDyY1hJ2r7-QuqzD_3fhRFwDoAR9G9Ru6P6f_Tf0ErMx8uQ</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Nguyen, Shaun A.</creator><creator>Walker, David</creator><creator>Gillespie, M. Boyd</creator><creator>Gutkind, J. Silvio</creator><creator>Day, Terry A.</creator><general>Current Science Inc</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20120301</creationdate><title>mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma</title><author>Nguyen, Shaun A. ; Walker, David ; Gillespie, M. Boyd ; Gutkind, J. Silvio ; Day, Terry A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-7cc6cd4cca61567bdce6d73a369e7400be3f940e88bc4402313c6202d4bebc2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - epidemiology</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Clinical Trials as Topic</topic><topic>Everolimus</topic><topic>Female</topic><topic>Head and Neck Cancer (T Day</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - epidemiology</topic><topic>Head and Neck Neoplasms - genetics</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Section Editor</topic><topic>Signal Transduction</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - pharmacokinetics</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Shaun A.</creatorcontrib><creatorcontrib>Walker, David</creatorcontrib><creatorcontrib>Gillespie, M. Boyd</creatorcontrib><creatorcontrib>Gutkind, J. Silvio</creatorcontrib><creatorcontrib>Day, Terry A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Shaun A.</au><au>Walker, David</au><au>Gillespie, M. Boyd</au><au>Gutkind, J. Silvio</au><au>Day, Terry A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>13</volume><issue>1</issue><spage>71</spage><epage>81</epage><pages>71-81</pages><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement
Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the three rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive preclinical data suggests that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients.</abstract><cop>New York</cop><pub>Current Science Inc</pub><pmid>22282394</pmid><doi>10.1007/s11864-011-0180-2</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-2729 |
| ispartof | Current treatment options in oncology, 2012-03, Vol.13 (1), p.71-81 |
| issn | 1527-2729 1534-6277 1534-5277 |
| language | eng |
| recordid | cdi_proquest_journals_1111872400 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Agents - pharmacokinetics Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - epidemiology Carcinoma, Squamous Cell - genetics Clinical Trials as Topic Everolimus Female Head and Neck Cancer (T Day Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - epidemiology Head and Neck Neoplasms - genetics Humans Male Medicine Medicine & Public Health Oncology Section Editor Signal Transduction Sirolimus - analogs & derivatives Sirolimus - pharmacokinetics TOR Serine-Threonine Kinases - antagonists & inhibitors United States - epidemiology |
| title | mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A54%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=mTOR%20Inhibitors%20and%20its%20Role%20in%20the%20Treatment%20of%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Nguyen,%20Shaun%20A.&rft.date=2012-03-01&rft.volume=13&rft.issue=1&rft.spage=71&rft.epage=81&rft.pages=71-81&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-011-0180-2&rft_dat=%3Cproquest_cross%3E2788417831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1111872400&rft_id=info:pmid/22282394&rfr_iscdi=true |